127 related articles for article (PubMed ID: 32721452)
1. Design and synthesis of peptidic partial agonists of human neuromedin U receptor 1 with enhanced serum stability.
Takayama K; Mori K; Asari T; Sohma Y; Nomura E; Sasaki Y; Taguchi A; Taniguchi A; Miyazato M; Minamino N; Kangawa K; Hayashi Y
Bioorg Med Chem Lett; 2020 Sep; 30(18):127436. PubMed ID: 32721452
[TBL] [Abstract][Full Text] [Related]
2. Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2.
Takayama K; Mori K; Taketa K; Taguchi A; Yakushiji F; Minamino N; Miyazato M; Kangawa K; Hayashi Y
J Med Chem; 2014 Aug; 57(15):6583-93. PubMed ID: 24999562
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Human Neuromedin U Receptor 1-Selective Hexapeptide Agonist with Enhanced Serum Stability.
Takayama K; Mori K; Tanaka A; Nomura E; Sohma Y; Mori M; Taguchi A; Taniguchi A; Sakane T; Yamamoto A; Minamino N; Miyazato M; Kangawa K; Hayashi Y
J Med Chem; 2017 Jun; 60(12):5228-5234. PubMed ID: 28548497
[TBL] [Abstract][Full Text] [Related]
4. Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.
Kaisho T; Nagai H; Asakawa T; Suzuki N; Fujita H; Matsumiya K; Nishizawa N; Kanematsu-Yamaki Y; Dote K; Sakamoto JI; Asami T; Takekawa S
Int J Obes (Lond); 2017 Dec; 41(12):1790-1797. PubMed ID: 28757640
[TBL] [Abstract][Full Text] [Related]
5. Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide.
Kanematsu-Yamaki Y; Nishizawa N; Kaisho T; Nagai H; Mochida T; Asakawa T; Inooka H; Dote K; Fujita H; Matsumiya K; Hirabayashi H; Sakamoto J; Ohtaki T; Takekawa S; Asami T
J Med Chem; 2017 Jul; 60(14):6089-6097. PubMed ID: 28657315
[TBL] [Abstract][Full Text] [Related]
6. A chemically stable peptide agonist to neuromedin U receptor type 2.
Takayama K; Mori K; Tanaka A; Sasaki Y; Sohma Y; Taguchi A; Taniguchi A; Sakane T; Yamamoto A; Miyazato M; Minamino N; Kangawa K; Hayashi Y
Bioorg Med Chem; 2020 May; 28(10):115454. PubMed ID: 32247748
[TBL] [Abstract][Full Text] [Related]
7. Development of potent and proteolytically stable human neuromedin U receptor agonists.
De Prins A; Martin C; Van Wanseele Y; Skov LJ; Tömböly C; Tourwé D; Caveliers V; Van Eeckhaut A; Holst B; Rosenkilde MM; Smolders I; Ballet S
Eur J Med Chem; 2018 Jan; 144():887-897. PubMed ID: 29329072
[TBL] [Abstract][Full Text] [Related]
8. [Medicinal Chemistry Focused on Mid-sized Peptides Derived from Biomolecules].
Takayama K
Yakugaku Zasshi; 2019; 139(11):1377-1384. PubMed ID: 31685733
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into the peptide selectivity and activation of human neuromedin U receptors.
You C; Zhang Y; Xu P; Huang S; Yin W; Eric Xu H; Jiang Y
Nat Commun; 2022 Apr; 13(1):2045. PubMed ID: 35440625
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent hexapeptide agonists to human neuromedin u receptor 1 and identification of their serum metabolites.
Takayama K; Mori K; Sohma Y; Taketa K; Taguchi A; Yakushiji F; Minamino N; Miyazato M; Kangawa K; Hayashi Y
ACS Med Chem Lett; 2015 Mar; 6(3):302-7. PubMed ID: 25815150
[TBL] [Abstract][Full Text] [Related]
11. Small-Molecule Neuromedin U Receptor 2 Agonists Suppress Food Intake and Decrease Visceral Fat in Animal Models.
Sampson CM; Kasper JM; Felsing DE; Raval SR; Ye N; Wang P; Patrikeev I; Rytting E; Zhou J; Allen JA; Hommel JD
Pharmacol Res Perspect; 2018 Oct; 6(5):e00425. PubMed ID: 30151213
[TBL] [Abstract][Full Text] [Related]
12. PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes.
Ingallinella P; Peier AM; Pocai A; Marco AD; Desai K; Zytko K; Qian Y; Du X; Cellucci A; Monteagudo E; Laufer R; Bianchi E; Marsh DJ; Pessi A
Bioorg Med Chem; 2012 Aug; 20(15):4751-9. PubMed ID: 22771182
[TBL] [Abstract][Full Text] [Related]
13. Transnasal Delivery of the Peptide Agonist Specific to Neuromedin-U Receptor 2 to the Brain for the Treatment of Obesity.
Tanaka A; Takayama K; Furubayashi T; Mori K; Takemura Y; Amano M; Maeda C; Inoue D; Kimura S; Kiriyama A; Katsumi H; Miyazato M; Kangawa K; Sakane T; Hayashi Y; Yamamoto A
Mol Pharm; 2020 Jan; 17(1):32-39. PubMed ID: 31765157
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Pentapeptide Antagonist to Human Neuromedin U Receptor 1.
Takayama K; Mori K; Sasaki Y; Taguchi A; Taniguchi A; Miyazato M; Hayashi Y
ACS Med Chem Lett; 2024 Jun; 15(6):885-891. PubMed ID: 38894927
[TBL] [Abstract][Full Text] [Related]
15. Characterization of neuromedin U (NMU), neuromedin S (NMS) and their receptors (NMUR1, NMUR2) in chickens.
Wan Y; Zhang J; Fang C; Chen J; Li J; Li J; Wu C; Wang Y
Peptides; 2018 Mar; 101():69-81. PubMed ID: 29288685
[TBL] [Abstract][Full Text] [Related]
16. A potent neuromedin U receptor 2-selective alkylated peptide.
Nishizawa N; Kanematsu-Yamaki Y; Funata M; Nagai H; Shimizu A; Fujita H; Sakamoto J; Takekawa S; Asami T
Bioorg Med Chem Lett; 2017 Oct; 27(20):4626-4629. PubMed ID: 28935264
[TBL] [Abstract][Full Text] [Related]
17. Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2.
Liu JJ; Payza K; Huang J; Liu R; Chen T; Coupal M; Laird JM; Cao CQ; Butterworth J; Lapointe S; Bayrakdarian M; Trivedi S; Bostwick JR
J Pharmacol Exp Ther; 2009 Jul; 330(1):268-75. PubMed ID: 19369576
[TBL] [Abstract][Full Text] [Related]
18. Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.
Neuner P; Peier AM; Talamo F; Ingallinella P; Lahm A; Barbato G; Di Marco A; Desai K; Zytko K; Qian Y; Du X; Ricci D; Monteagudo E; Laufer R; Pocai A; Bianchi E; Marsh DJ; Pessi A
J Pept Sci; 2014 Jan; 20(1):7-19. PubMed ID: 24222478
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice.
Nagai H; Kaisho T; Yokoyama K; Asakawa T; Fujita H; Matsumiya K; Noguchi J; Tsuchimori K; Nishizawa N; Kanematsu-Yamaki Y; Dote K; Inooka H; Sakamoto JI; Ohtaki T; Asami T; Takekawa S
Br J Pharmacol; 2018 Jan; 175(2):359-373. PubMed ID: 29057457
[TBL] [Abstract][Full Text] [Related]
20. Increased NMUR1 Expression in Mast Cells in the Synovial Membrane of Obese Osteoarthritis Patients.
Tsukada A; Takata K; Takano S; Ohashi Y; Mukai M; Aikawa J; Iwase D; Inoue G; Takaso M; Uchida K
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
